Genelux Corporation (NASDAQ:GNLX) Receives Consensus Rating of "Buy" from Brokerages

Genelux Corporation (NASDAQ:GNLX - Get Free Report) has been given an average rating of "Buy" by the five analysts that are covering the stock, MarketBeat reports. Four research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $17.75.

A number of equities analysts recently issued reports on the company. Benchmark reduced their target price on Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research note on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Genelux in a report on Monday, March 31st. Finally, Wall Street Zen lowered shares of Genelux from a "hold" rating to a "sell" rating in a research report on Saturday.

Genelux Stock Up 0.4%

Shares of GNLX traded up $0.01 during mid-day trading on Wednesday, hitting $2.84. 47,765 shares of the company traded hands, compared to its average volume of 195,513. The company has a market capitalization of $107.18 million, a PE ratio of -3.23 and a beta of -0.35. The business has a 50 day moving average of $2.70 and a 200 day moving average of $3.09. Genelux has a 1-year low of $1.60 and a 1-year high of $5.89.

Genelux (NASDAQ:GNLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.03. As a group, research analysts expect that Genelux will post -0.88 EPS for the current fiscal year.

Institutional Trading of Genelux

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of Genelux in the fourth quarter worth about $25,000. Advisor Resource Council acquired a new position in Genelux in the 1st quarter worth about $34,000. Raymond James Financial Inc. purchased a new position in Genelux during the fourth quarter worth approximately $41,000. Liberty Wealth Management LLC purchased a new position in Genelux during the first quarter worth approximately $45,000. Finally, 5T Wealth LLC acquired a new stake in Genelux in the first quarter valued at approximately $49,000. Institutional investors and hedge funds own 37.33% of the company's stock.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.